Sarcoma Diagnosis and Treatment: Navigating the NGS Controversy
The Promise and Pitfalls of Next-Generation Sequencing (NGS) in Cancer Care.
A recent consensus statement reveals a fascinating yet complex scenario in the world of sarcoma treatment. While NGS holds immense potential for 'tumor-agnostic' therapies, its routine use in clinical care and diagnosis of sarcomas is not yet supported by evidence. But why? After all, NGS is a powerful tool for identifying biomarkers and guiding future therapies.
Here's the twist: Sarcomas are an incredibly diverse group of cancers, with over 70 subtypes and numerous ultrarare forms. However, they share a common challenge: a low mutational burden, which makes precision oncology approaches more difficult. And this is where NGS comes into play, offering a glimmer of hope.
Unraveling the NGS Enigma in Sarcoma Care:
A multidisciplinary team of sarcoma experts has delved into this conundrum, publishing their findings in JAMA Oncology. They acknowledge that NGS technologies are becoming more accessible, but their routine use in sarcoma care lacks robust evidence. The key lies in understanding the unique characteristics of sarcomas.
Sarcomas can be genomically simple or complex, yet they often share a remarkably low mutational burden. Misdiagnosis rates are high, reaching 10-25% when not reviewed by experts. The diagnostic and therapeutic landscape is fragmented, adding to the complexity. But NGS offers a beacon of light, identifying 'tumor-agnostic targets' and heritable genetic predispositions.
The Power and Limitations of NGS:
NGS is not yet part of routine clinical care, but it's poised to revolutionize sarcoma treatment. It can advance our molecular understanding and identify biomarkers, especially for ultrarare subtypes. However, the rarity, heterogeneity, and limited molecular knowledge of sarcomas present significant challenges. This has led to a gap in guidelines for NGS use.
The consensus reached by the experts is eye-opening. While NGS can identify genetic alterations, only a small percentage of sarcomas have actionable mutations, and the benefit of matched treatments is limited. And here's where it gets controversial: there were no standardized recommendations for NGS use in sarcoma care before this consensus.
The Way Forward: Optimizing NGS in Sarcoma Research and Diagnosis:
The consensus encourages a research-oriented approach, advocating for sequencing all sarcomas using pangenomic tools like whole-genome sequencing with RNA sequencing. The addition of whole transcriptome sequencing is a game-changer, as RNA expression data can guide therapeutic decisions. This is particularly impactful for rare cancers like sarcomas.
The experts agree that NGS fusion panels are not necessary for all new sarcoma cases, as most subtypes have distinct histologic features. Complex karyotypes, for instance, are unlikely to benefit from molecular testing. Traditional pathology and targeted tests remain essential for accurate diagnosis.
The clinical benefit rate of NGS is surprisingly low, estimated at only 0.4%. This underscores the importance of accurate subtype diagnosis for targeted therapies. NGS results should be interpreted by expert pathologists and multidisciplinary teams to ensure appropriate treatment.
Practical Implications and Recommendations:
For managed care organizations, the message is clear: NGS should be used selectively. Routine testing for all sarcoma patients is not advised. Instead, focus on specific subtypes and scenarios where actionable alterations are probable. Referring patients to expert centers can improve diagnostic accuracy, reduce costs, and enhance outcomes.
And this is the part most people miss: ensuring NGS results are reviewed by molecular tumor boards is crucial. Integrating clinical, pathologic, and molecular data can lead to more informed treatment decisions.
The NGS journey in sarcoma care is a delicate balance between embracing innovation and ensuring evidence-based practice. As we move forward, the consensus guidelines will undoubtedly shape the future of sarcoma diagnosis and treatment, sparking discussions and debates along the way.
